Active Pharmaceutical Ingredient for Cancer Market Share

Global Active Pharmaceutical Ingredient for Cancer Market Overview

Active Pharmaceutical Ingredient for Cancer Market Size was valued at USD 2.03 Billion in 2023. 

The Global Active Pharmaceutical Ingredient for Cancer industry is projected to grow from USD 2.18 Billion in 2024 to USD 3.81 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period (2024 - 2032). 

API for cancer market, including conventional syringes, needle-free injectors, and auto and pen injectors have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The market for API for cancer has witnessed continuously rising R&D. As a result, the active pharmaceutical ingredient for cancer market is fragmented into various advanced products as per the molecules. 

Following the illustrated course, it is projected that increasing prevalence of cancer, growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs drives the market growth. However, side effects associated with the medication are estimated to restrain the market growth during the forecast period.

Active Pharmaceutical Ingredient for Cancer Market Trends

The active pharmaceutical ingredient for cancer market is driven by increasing prevalence of cancer drives the market growth. According to the statistical report published by the World Health Organization (WHO) in 2020, approximately 19.3 million new cases of cancer were diagnosed worldwide. This indicates a potential for growth in the global API for cancer market.

The other factors that are driving the global API for cancer market are growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs, and others.

Active Pharmaceutical Ingredient for Cancer Market Segmentation

The global API for cancer market has been segmented into by type, indications, and end users.

Based on type it is segmented into tinib, parib, rafenib, lisib, degib, ciclib, and others

Based on indication, it is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others.

Based on end user, the market is segmented into pharmaceutical companies, research organizations, others.

Active Pharmaceutical Ingredient for Cancer Market Key Players

The prominent players in the global API for cancer market are AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.

Active Pharmaceutical Ingredient for Cancer Market Regional Analysis

The global API for cancer market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is anticipated to dominate the global API for cancer market owing to the rising awareness about the condition and high healthcare expenditure. The Americas is expected to reach USD 34,300.00 million by 2025 at a CAGR of 8.1% from 2023 to 2032. The Americas region accounted largest regional market owing to the growing biotechnology industry, the growing prevalence of cancer, and a highly developed healthcare sector.  

Europe accounted for the second-largest market share in 2018 due to extensive R&D for healthcare, increasing funding, and growing adoption of the technology within the region.

On the other hand, the Middle East and Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.

Key Updates

• In May 2019, Eli Lilly and Company received US Food and Drug Administration approval for its drug Cyramza (ramucirumab) a human VEGFR2 antagonist. It is a recombinant molecule of the human IgG1 monoclonal antibody.

• In April 2019 Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor.

Market Segmentation

Global Active Pharmaceutical Ingredient for Cancer Market, by Type

• Tyrosine Kinase Inhibitor (Tinib)




• Ponatinib


• Brigatinib


• Ruxolitinib


• Erlotinib


• Alectinib


• Cobimetinib


• Neratinib


• Osimertinib


• Acalabrutinib


• Bosutinib


• Crizotinib


• Axitinib


• Sunitinib


• Ceritinib


• Imatinib


• Lapatinib


• Afatinib


• Cabozantinib


• Dasatinib


• Ibrutinib


• Lenvatinib


• Gefitinib


• Others




• Proteasome Inhibitors (Parib)




• Olaparib


• Rucaparib


• Niraparib


• BRAF Kinase Inhibitors (rafenib)


• Sorafenib


• Regorafenib


• Vemurafenib


• Dabrafenib


• Enasidenib


• Others




• Phosphatidylinositol 3-Kinase Inhibitors (Lisib)




• Idelalisib


• Copanlisib




• SMO Receptor Antagonists (Degib)




• Sonidegib


• Vismodegib




• Cyclin Dependent Kinase Inhibitors (Ciclib)




• Palbociclib


• Ribociclib


• Abemaciclib




• Others

Global API for Cancer Market, by Indication

• Blood Cancer


• Skin Cancer


• Lungs Cancer


• Breasts Cancer


• Pancreas Cancer


• Others

Global Active Pharmaceutical Ingredient for Cancer Market, by End User

• Pharmaceutical Companies


• Research Organizations


• Others

Global Active Pharmaceutical Ingredient for Cancer Market, by Region

• Americas




• North America




• US


• Canada




• Latin America

• Europe




• Western Europe




• Germany


• UK


• France


• Italy


• Spain


• Rest of Western Europe




• Eastern Europe

• Asia-Pacific




• China


• Japan


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Available Additional Customizations

• Additional Companies


• Supply & Demand Analysis

Intended Audience

• Pharmaceutical Companies


• Hospitals and Clinics


• Regulatory Agencies


• Research Institutes